Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sotetsuflavone is a naturally occurring biflavonoid compound isolated from plants such as Cycas revoluta and Taxus cuspidata. It exhibits notable anti-cancer properties in preclinical studies. Mechanistically, sotetsuflavone inhibits proliferation, migration, and invasion of non-small cell lung cancer (NSCLC) cells by inducing apoptosis (via upregulation of cytochrome C, cleaved-caspase 3/9 and Bax; downregulation of Bcl-2), causing G0/G1 cell cycle arrest (by reducing cyclin D1 and CDK4), and promoting autophagy through inhibition of the PI3K/Akt/mTOR signaling pathway. Additionally, it is a potent inhibitor of Dengue virus NS5 RNA-dependent RNA polymerase with an IC50 value around 0.16 μM[2][4][5]. Sotetsuflavone has not been approved for clinical use but shows promise as an anti-tumor agent in preclinical models.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sotetsuflavone.